Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Track (GIT) Symptoms in Thailand (GerdQ)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: October 20, 2009
Last updated: March 30, 2011
Last verified: March 2011
This is a prospective , epidemiological, multi-centre, phase IV study, approximately 5,000 patients who suffer with upper gastrointestinal tract symptoms. Each patient will be assessed for GERD with GerdQ Thai Version.

Upper GIT Symptoms

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Prevalence of GERD in Patients With upperGITsymptoms in Thailand

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Prevalence of gastroesophageal reflux disease (GERD) in patients presented with upper gastrointestinal tract symptoms [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Response to various treatments for patients who have been diagnosed of GERD [ Designated as safety issue: No ]

Enrollment: 4108
Study Start Date: December 2009
Study Completion Date: February 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Primary care clinic

Inclusion Criteria:

  • Provision of informed consent prior to any study specific procedures
  • Female or male aged at least 18 years
  • Patient must be having symptoms suggestive of upper gastrointestinal tract symptoms such as heart burn/ regurgitation

Exclusion Criteria:

  • Involvement in the planning and /or conduct of the study (applies to both AstraZeneca staff and /or staff at study site
  • Participation in a clinical study(excluding non-interventional study or registry) during the last 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00999063

Research Site
Bangkok Noi, Bangkok, Thailand
Research Site
Muang, Bangkok, Thailand
Research Site
Pathumwan, Bangkok, Thailand
Research Site
Rajthevee, Bangkok, Thailand
Research Site
Ratchthewi, Bangkok, Thailand
Research Site
Maerim, Chiang Mai, Thailand
Research Site
Maung, Chiang Mai, Thailand
Research Site
Maung, Khon Kaen, Thailand
Research Site
Maung, Nakhon Sri Thammarat, Thailand
Research Site
Maung, Nakhonratchasima, Thailand
Research Site
Maung, Nakhonsawan, Thailand
Research Site
Maung, Nakornpathom, Thailand
Research Site
Muang, Nonthaburi, Thailand
Research Site
Klong Luang, Pathumthani, Thailand
Research Site
Maung, Phetchabun, Thailand
Research Site
Maung, Phuket, Thailand
Research Site
Maung, Rajburi, Thailand
Research Site
Maung, Roiet, Thailand
Research Site
Maung, Samut sakorn, Thailand
Research Site
Maung, Sukhothai, Thailand
Research Site
Maung, Trang, Thailand
Research Site
Maung, Ubonratchathani, Thailand
Research Site
Varin Chamrap, Ubonratchathani, Thailand
Research Site
Muang, Udon Thani, Thailand
Research Site
Maung, Uttaradit, Thailand
Sponsors and Collaborators
Principal Investigator: Somchai Leelasukolvong, Dr. Siriraj Hospital
  More Information

Responsible Party: Sompob Paibulsirijit, MD, Vice President Medical& Regulatory Affairs department, AstraZeneca Identifier: NCT00999063     History of Changes
Other Study ID Numbers: NIS-GTH-NEX-2009/1 
Study First Received: October 20, 2009
Last Updated: March 30, 2011
Health Authority: Thailand: Ethical Committee
Thailand: Food and Drug Administration
Thailand: Khon Kaen University Ethics Committee for Human Research
Thailand: Ministry of Public Health

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Gastroesophageal Reflux
Deglutition Disorders
Digestive System Diseases
Esophageal Diseases
Esophageal Motility Disorders
Gastrointestinal Diseases processed this record on May 26, 2016